Stage (next event)
Phase 2 (Data)
Catalyst Info & Data Links
We will not be following this anymore because AIMT was bought by Nestle
NCT04056299: Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy
August 21, 2019: Phase 2 Enrollment
PALISADE Group of Clinical Investigators. (2018). AR101 oral immunotherapy for peanut allergy. New England Journal of Medicine, 379(21), 1991-2001.
Wambre, E., Bajzik, V., DeLong, J. H., O’Brien, K., Nguyen, Q. A., Speake, C., ... & Farrington, M. (2017). A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders. Science translational medicine, 9(401), eaam9171.
Mechanism of Action
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post